13 research outputs found
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
Full text linkThe mobile angiograph in a center without on-site surgical back-up: the de facto standard?
No full textIntracranial Hemorrhage Following Neuroendovascular Procedures with Abciximab is Associated with High Mortality: A Multicenter Series
No full textDevelopment of glycoprotein IIb–IIIa antagonists: translation of pharmacodynamic effects into clinical benefit
No full text
Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents
No full textPharmacologic advances in the use of antithrombotic agents have paralleled the technologic innovations used in patients undergoing coronary interventions. The recognition of the central role of platelets in the development of complications related to coronary interventions led to the investigation and subsequent routine use of several antiplatelet agents as adjuvants to coronary intervention. Thus, the oral agents aspirin and either ticlopidine or clopidogrel are routinely administered after coronary stenting. Intravenous glycoprotein (GP) IIb/IIIa antagonists have been extensively studied and reduce adverse cardiac events in patients undergoing coronary interventions, especially those receiving intracoronary stents. Despite the growing use of GP IIb/IIIa antagonists, much information remains unknown as to the proper dosing and the effects these agents have on other elements of the hemostatic and vascular systems
Antithrombotic therapy in the cardiac catheterization laboratory: Focus on antiplatelet agents
No full textOngoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design
No full text
